Affiliation:
1. U1292, Laboratoire de BioSanté, Institut National de la Santé et de la Recherche Médicale (INSERM), F-38058 Grenoble, France
2. Commissariat à l’Energie Atomique (CEA), DSV-IRIG, F-38054 Grenoble, France
3. University of Grenoble Alpes (UGA), F-38058 Grenoble, France
Abstract
The cellular prion protein (PrPC) is a glycoprotein anchored to the cell surface by glycosylphosphatidylinositol (GPI). PrPC is expressed both in the brain and in peripheral tissues. Investigations on PrPC’s functions revealed its direct involvement in neurodegenerative and prion diseases, as well as in various physiological processes such as anti-oxidative functions, copper homeostasis, trans-membrane signaling, and cell adhesion. Recent findings have revealed the ectopic expression of PrPC in various cancers including gastric, melanoma, breast, colorectal, pancreatic, as well as rare cancers, where PrPC promotes cellular migration and invasion, tumor growth, and metastasis. Through its downstream signaling, PrPC has also been reported to be involved in resistance to chemotherapy and tumor cell apoptosis. This review summarizes the variance of expression of PrPC in different types of cancers and discusses its roles in their development and progression, as well as its use as a potential target to treat such cancers.
Funder
Institut National de la Santé et de la Recherche Médicale
University Grenoble-Alpes
VALO-GRAL CBH-EUR-GS
Région Auvergne-Rhône-Alpes/Cancéropôle Lyon Au-vergne Rhône-Alpes
Ligues Départementales (Isère & Savoie) contre le Cancer
ARC
Fondation pour la Recherche Médicale
GRAL, a program of the Chemistry Biology Health Graduate School of Université Grenoble Alpes
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献